LXRX News Alert Lexicon Pharmaceuticals (LXRX) 0.85 12/13/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lexicon Pharmaceuticals (LXRX) 0.85 $LXRX

Lexicon To Present At The Oppenheimer 25th Annual Healthcare Conference
PR Newswire - Mon Dec 08, 5:02PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10, 2014 at 4:30 PM EST in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 0.85 (-0.05)

Arthritis - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/42nbjz/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Eli Lilly and Company - GlaxoSmithKline - Nemucore Medical Innovations - Taisho Pharmaceutical - Sylentis - Astellas Pharma - Eisai - Bone Medical - Momenta Pharmaceuticals - Can-Fite BioPharma - Lexicon Pharmaceuticals - CSL Limited - WhanIn Pharmaceutical - Oscotec Inc. - Viron Therapeutics - PLx Pharma - Endocyte - Cardax Pharmaceuticals - Taiwan Liposome Company - NasVax - CalciMedica - Zyngenia - SelectX Pharmaceuticals - DoNatur - CellAct Pharma - Arcarios - Inbiopro Solutions - Sagene Pharmaceuticals - vida therapeutics - Dong-A Socio For more information visit http://www.researchandmarkets.com/research/42nbjz/arthritis
CANF: 3.49 (+0.03), LXRX: 0.85 (-0.05), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), MNTA: 12.16 (-0.04)

Lexicon concludes USD280m in concurrent financing transactions
M2 - Fri Nov 28, 3:01AM CST
Biopharmaceutical company Lexicon Pharmaceuticals (NasdaqGS:LXRX) disclosed on Thursday the completion of the concurrent transactions for gross proceeds of USD280.0m.
LXRX: 0.85 (-0.05)

InsiderInsights.com Daily Round Up 11/26/14: VRX, INTX, AEHR, HRG
InsiderInsights - at Seeking Alpha - Wed Nov 26, 11:53PM CST

SC: 17.65 (-0.71), VRX: 138.71 (-0.18), LXRX: 0.85 (-0.05), NEOT: 7.49 (-0.48), AEHR: 2.65 (-0.05), BBY: 36.85 (+0.22), SGM: 11.60 (-0.29), FIVE: 37.39 (+0.24), INTX: 4.20 (+0.05), SPW: 79.82 (-2.48), REXX: 5.18 (+0.03), HRG: 13.10 (-0.19), PF: 34.46 (-0.23), PGRE: 18.34 (-0.08), AAPL: 109.73 (-1.89), INTU: 92.17 (-1.20), CSCO: 26.85 (-0.14), KPTI: 34.85 (+1.35)

Lexicon Announces Completion Of $280 Million In Financing Transactions
PR Newswire - Wed Nov 26, 3:01PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the completion of previously announced concurrent financing transactions resulting in gross proceeds of $280.0 million. After fees and estimated offering expenses, Lexicon anticipates net proceeds of approximately $273.7 million from the transactions. The transactions consisted of:
LXRX: 0.85 (-0.05)

A Change In Strategy: Lexicon Pharmaceuticals
Samuel Riehn - at Seeking Alpha - Sun Nov 23, 11:04PM CST

LXRX: 0.85 (-0.05)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 11:46AM CST

LEJU: 10.83 (-0.01), GEOS: 24.93 (-0.45), LXRX: 0.85 (-0.05), OTIV: 1.68 (-0.06), GME: 32.30 (-1.61), ARUN: 19.49 (-0.03), NBS: 3.58 (+0.31), PHMD: 1.37 (-0.10), AMDA: 0.69 (-0.01), CANF: 3.49 (+0.03), MOLG: 2.90 (-0.05), WAIR: 13.53 (+0.05), EDAP: 2.15 (+0.02), FWM: 2.83 (-0.12), GERN: 3.24 (+0.01), OCRX: 6.10 (-0.05), NGVC: 25.93 (-0.38), SFUN: 7.73 (+0.06), EJ: 8.28 (-0.10), BGI: 1.40 (-0.08)

Lexicon Pharmaceuticals Fights On
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 21, 11:09AM CST

LXRX: 0.85 (-0.05)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 8:13AM CST

NETE: 1.16 (-0.12), ANV: 0.74 (-0.04), EXXI: 2.84 (unch), LXRX: 0.85 (-0.05), OTIV: 1.68 (-0.06), GME: 32.30 (-1.61), ARUN: 19.49 (-0.03), GFI: 4.29 (-0.17), CLF: 6.74 (-0.20), NYMT: 7.82 (-0.08), AMDA: 0.69 (-0.01), MOLG: 2.90 (-0.05), SID: 1.67 (-0.14), SCTY: 50.02 (-0.89), VALE: 7.19 (-0.07), SFUN: 7.73 (+0.06), GOL: 5.43 (-0.24), SPLK: 55.77 (-1.49), ICLD: 3.01 (-0.05), BBL: 41.42 (-1.25), ROST: 90.58 (-0.24)

How To Be Smarter About Risk Management
Morningstar - Seeking Alpha - Fri Nov 21, 7:00AM CST
By Alex Bryan Note: This article is part of Morningstar's November 2014 Risk Management Week special report. An earlier version appeared Aug. 13, 2014. In isolation, risk is neither good nor bad. Finance 101 teaches that the market must offer...
MMM: 157.12 (-2.03), SPY: 200.89 (-3.30), SPLV: 36.88 (-0.55), LXRX: 0.85 (-0.05), QUAL: 61.00 (-0.88), USMV: 39.76 (-0.53)

Lexicon prices public offering at USD1.005 per share
M2 - Fri Nov 21, 6:05AM CST
Biopharmaceutical company Lexicon Pharmaceuticals (NasdaqGS:LXRX) said on Thursday that it has priced a public offering of USD50m shares of its common stock.
LXRX: 0.85 (-0.05)

Lexicon Announces Pricing Of Convertible Senior Notes Offering
PR Newswire - Fri Nov 21, 12:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has priced its offering of $80,000,000 aggregate principal amount of 5.25% Convertible Senior Notes due 2021 (the "Convertible Notes" in a private offering within the United States. The Convertible Notes were offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act" . Lexicon has also granted the initial purchasers an option to purchase up to an additional $15,000,000 aggregate principal amount of the Convertible Notes on the same terms and conditions, solely to cover over-allotments. Lexicon expects to close the offering on November 26, 2014, subject to the satisfaction of customary closing conditions.
LXRX: 0.85 (-0.05)

Lexicon Announces Pricing Of Common Stock Offering
PR Newswire - Fri Nov 21, 12:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the pricing of its previously announced underwritten public offering of $50,000,000 of shares of its common stock pursuant to an effective shelf registration statement. The offering will consist of 49,751,244 shares of common stock at a public offering price of $1.005 per share. Lexicon has also granted the underwriters a 30-day option to purchase up to 7,462,687 additional shares of common stock. All of the shares in the offering will be sold by Lexicon. J.P. Morgan Securities, LLC and Goldman, Sachs & Co. are acting as joint book-runners for the offering and Needham & Company, LLC and Stifel, Nicolaus & Company, Incorporated are acting as co-managers for the offering. Lexicon expects to close the offering on November 26, 2014, subject to the satisfaction of customary closing conditions.
JPM: 60.04 (-1.10), LXRX: 0.85 (-0.05)

Lexicon drops on dilutive stock offering
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 11:35AM CST

LXRX: 0.85 (-0.05)

Stock to Watch: Lexicon Pharmaceuticals Down 17.0% (LXRX)
Comtex SmarTrend(R) - Thu Nov 20, 10:08AM CST
Lexicon Pharmaceuticals (NASDAQ:LXRX) is one of today's worst performing low-priced stocks, down 17.0% to $1.04 on 3.9x average daily volume. Thus far today, Lexicon Pharmaceuticals has traded 4.0 million shares, vs. average volume of 1.0 million shares per day. The stock has underperformed the Dow (-17.0% to the Dow's -0.0%) and underperformed the S&P 500 (-17.0% to the S&P's 0.1%) during today's trading.
LXRX: 0.85 (-0.05)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 8:15AM CST

GPRO: 60.52 (+0.47), ANV: 0.74 (-0.04), WD: 16.42 (-0.14), LXRX: 0.85 (-0.05), JMEI: 13.50 (-0.01), LOCO: 22.88 (+0.60), MAGS: 5.35 (+0.09), WSM: 72.16 (-0.52), CZR: 12.83 (-2.03), ITUB: 12.62 (-0.61), MBLY: 40.78 (-1.19)

Lexicon Pharma to sell USD50m common stock in public offering
M2 - Thu Nov 20, 5:34AM CST
Biopharmaceutical company Lexicon Pharmaceuticals (NasdaqGS:LXRX) said on Wednesday that it plans to sell USD50m shares of its common stock in a public offering.
LXRX: 0.85 (-0.05)

Lexicon proposes offering of USD75m convertible senior notes
M2 - Thu Nov 20, 5:34AM CST
Biopharmaceutical company Lexicon Pharmaceuticals (NasdaqGS:LXRX) said on Wednesday that it intends to to sell USD75m aggregate principal amount of convertible senior notes due 2021 in a private offering that is subject to market and other conditions.
LXRX: 0.85 (-0.05)

Lexicon Announces Proposed Common Stock Offering
PR Newswire - Wed Nov 19, 3:01PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it commenced an offering to sell, subject to market and other conditions, $50,000,000 of shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Lexicon also intends to grant the underwriters a 30-day option to purchase up to $7,500,000 of additional shares of common stock. All of the shares in the offering are to be sold by Lexicon. J.P. Morgan Securities, LLC and Goldman, Sachs & Co. will be acting as joint book-runners for the offering and Needham & Company, LLC and Stifel, Nicolaus & Company, Incorporated will be acting as co-managers for the offering.
JPM: 60.04 (-1.10), LXRX: 0.85 (-0.05)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 122

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 491

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 307

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 20

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 74

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 207

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 75

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 58

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 160

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza

Updated Category News Views 14

Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...

Continue Reading

Top 5 Most Recently Viewed Articles

Genius Group Takes Center Stage at Major Investor Events

Updated Category News Views 214

Genius Group Highlights Major Sponsorships in 2025 Genius Group Limited (NYSE: GNS), an AI-driven education enterprise that prioritizes Bitcoin, has announced its participation in two pivotal investor summits. These events provide a significant platform for the company to engage with institutional investors and emphasize its innovative approach to digital assets. Engaging...

Continue Reading
Miami International Holdings Celebrates Robust Q3 Growth

Updated Category News Views 172

Miami International Holdings Reports Strong Financial Performance Miami International Holdings, Inc. (MIH) (NYSE: MIAX) has recently announced impressive financial outcomes for its third quarter, highlighting a remarkable growth trend. The financial data unveiled reflects the organization's ability to thrive in a highly competitive landscape. With a net revenue increase...

Continue Reading
Market Insights: Momo Crowd and GM's Tariff Burdens

Updated Category News Views 382

Understanding Momo Crowd Dynamics in Today's Market The stock market consistently reflects a myriad of influences, one of which is the behavior of retail investors, commonly referred to as the 'momo crowd.' Recent analyses indicate that the actions of these investors can significantly shape market trends, especially during times of heightened volatility. The Cautionary...

Continue Reading
Cathie Wood Praises Shopify: The Future of AI in Retail Awaits

Updated Category News Views 129

Cathie Wood's Enthusiastic Endorsement of Shopify ARK Invest, led by the visionary Cathie Wood, has recently expressed considerable confidence in Shopify Inc. SHOP. This faith stems from the company's forward-thinking approach toward artificial intelligence, particularly their dedicated focus on what they call 'agentic AI'. As the retail landscape evolves, many investors...

Continue Reading
Liftoff IPO: What’s the Real Play Behind the Curtain?

Updated Category News Views 244

Liftoff Mobile's been in the game since day one—on February 17, 2026, they dropped a bombshell, submitting their draft registration statement for an initial public offering (IPO) with the SEC. But hold your horses: nobody knows how many shares will float or what price range they’re angling for. That vagueness? Classic Wall Street move to stir up speculation while...

Continue Reading